Guangzhou Fuda Cancer Hospital, Beijing Genomics Institute Join Hands for Cancer Treatment

In the morning of March 16, 2016, Guangzhou Fuda Cancer Hospital and BGI (Beijing Genomics Institute) Group signed a Strategic Alliance Agreement with an aim of enhancing the cooperation between the two sides to make a breakthrough in performing accurate cancer treatment and implementing effective postoperative monitoring. BGI enjoys enormous advantages in the building and application of big platform while its research on diseases needs data support and intellectual support from hospital. The marriage between FUDA and BGI is of great importance to improve the cure rate of cancer and bring benefits to the society in the end.

Since its initiation in 1999, BGI has developed itself into the biggest genomic research center in the world. It has carried out research on over 12,000 samples of more than 20 types of cancer at home and abroad. At present, it has developed cooperation with more than 100 scientific research centers and more than 20 enterprises and institutions. It has launched research on birth defect, metabolic disease and malignant tumors. Hence, it hopes to cooperate with Fuda Cancer Hospital to launch Cross-Omics Plan on One Million Cases of Tumors so as to realize the calibration, qualitative determination, location, quantification, timing and strategy-making for tumors. 

Zhao Lijian, Vice President of BGI noted that conventional treatments for cancer, such as operation, chemotherapy, etc. cannot eliminate cancer radically. The scientific treatment method should be to identify the type of cancer from diagnosis and then analyze at the genetic level which drugs that are most suitable for the type of cancer diagnosis. “Beyond that, we hope to be able to identify the possibility of tumor recurrence and metastases by non-invasive gene test, which is easy in operation and low in cost.”

Xu Kecheng, Chief President of Guangzhou Fuda Cancer Hospital noted that over the past ten years, Fuda Cancer Hospital has been committing to treat advanced cancer--a difficult medical problem in the world with “3C+P” treatment model dominated by cryosurgical ablation (CSA), cancer microvascular intervention (CMI) and combined immunotherapy for cancer (CIC) with an aim of prolonging patients~ life and improving their quality of life. FUDA has been leading the world in terms of the number of cases and types of cancer that CSA has treated; FUDA has also made breakthrough achievements in treating central lung cancer, great hepatic carcinoma, and pancreatic cancer with CSA, which has won several awards for FUDA at home and abroad. In June, 2015, FUDA introduced NanoKnife equipment from America and carried out the first NanoKnife on pancreatic cancer in mainland China on July 2, 2015. As of now, FUDA has completed 100 cases of NanoKnife, the number of which ranks the first in China.

Xu Kecheng noted that Guangzhou Fuda Cancer Hospital has established its own cancer institute with its own scientific research team. FUDA-BGI strategic alliance allows experts on both sides to carry out concrete discussion on the cooperation vision and feasibility of the building and application of tumor sample data base, tumor detection at molecular level and the screening and early warning of high risk group by combining cancer high incidence scene and high-throughput sequencing.